Ultralife (NASDAQ:ULBI) Announces Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Ultralife (NASDAQ:ULBI) released its quarterly earnings data on Friday. The technology company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.18), Zacks reports. Ultralife had a positive return on equity of 3.10% and a negative net margin of 3.09%.

Here are the key takeaways from Ultralife’s conference call:

• Q1 revenue was $47.4 million with an operating loss of $0.2 million and a net loss of $0.5 million (‑$0.03/sh), attributed to shipment timing, Middle East delivery delays, plant reorganizations, weather-related interruptions, and pre‑revenue staffing and consulting costs.
• Consolidated gross margin dropped to 21.3% (down 380 bps) and gross profit fell 20.7% year‑over‑year, driven largely by lost production days (Newark substation failure and a 16‑day equivalent impact at Raynham during ERP/inventory transition), higher energy costs, and unfavorable sales mix/tariffs.
• The company exited Q1 with a record backlog of $115.1 million (up 21% YoY), representing 61% of trailing‑12‑month sales and including over $12 million of new‑product backlog, providing stronger near‑term revenue visibility.
• Management is investing in product development and vertical integration (Electrochem), expects to more than double internal cell usage, shipped the first conformal wearable battery order with > $8 million backlog, and won a $4 million multi‑year award—actions intended to stabilize Communications Systems revenue and lift gross margins.

Ultralife Stock Performance

ULBI traded down $1.08 on Friday, hitting $5.97. The company’s stock had a trading volume of 131,366 shares, compared to its average volume of 44,552. The company’s 50 day simple moving average is $6.64 and its 200-day simple moving average is $6.30. The firm has a market cap of $99.46 million, a P/E ratio of -16.58 and a beta of 0.74. Ultralife has a 12 month low of $4.78 and a 12 month high of $9.52. The company has a quick ratio of 1.39, a current ratio of 2.83 and a debt-to-equity ratio of 0.35.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Empowered Funds LLC bought a new position in Ultralife in the 4th quarter valued at $44,000. Lazard Asset Management LLC boosted its holdings in Ultralife by 1,650.0% in the 2nd quarter. Lazard Asset Management LLC now owns 5,565 shares of the technology company’s stock valued at $49,000 after purchasing an additional 5,247 shares during the period. Prelude Capital Management LLC bought a new position in Ultralife in the 3rd quarter valued at $71,000. Jane Street Group LLC bought a new position in Ultralife in the 4th quarter valued at $75,000. Finally, Jones Financial Companies Lllp boosted its holdings in Ultralife by 1,428.7% in the 1st quarter. Jones Financial Companies Lllp now owns 15,287 shares of the technology company’s stock valued at $82,000 after purchasing an additional 14,287 shares during the period. 30.68% of the stock is owned by institutional investors.

About Ultralife

Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.